logo

Aldeyra Therapeutics, Inc. (ALDX)



Trade ALDX now with
  Date
  Headline
4/24/2018 8:04:39 AM Aldeyra Therapeutics Announces First Patient Enrolled In Allergic Conjunctivitis Phase 3 Clinical Trial
3/29/2018 7:37:49 AM Aldeyra Therapeutics FY Net Loss $22.3 Mln Vs Loss $18.7 Mln Last Year
2/21/2018 8:08:38 AM Aldeyra Therapeutics Selected For Podium Presentation Of Phase 2a Dry Eye Disease Results
1/30/2018 8:07:31 AM Aldeyra Therapeutics Enrolls First Patient In Phase 2b Clinical Trial Of Topical Ocular Reproxalap
11/29/2017 8:05:37 AM Aldeyra Presents Noninfectious Anterior Uveitis Phase 2 Trial Data To The American Uveitis Society Held
11/9/2017 7:36:10 AM Aldeyra Therapeutics Q3 Loss Per Share $0.32 Vs Loss $0.38 Last Year
10/24/2017 8:11:39 AM Aldeyra Therapeutics Presents Evidence For Aldehyde Sequestration As Potential Therapeutic Approach
10/5/2017 8:09:15 AM Aldeyra Presents Novel Data On The Efficacy Of ADX-102 In Model Of Succinic Semialdehyde Dehydrogenase Activity
9/19/2017 8:59:01 AM Aldeyra Therapeutics Prices Public Offering Of 3.45 Mln Common Shares At $7.25 Per Share
9/18/2017 4:03:56 PM Aldeyra Therapeutics Announces Proposed Public Offering Of Common Stock
9/12/2017 7:07:13 AM Aldeyra Therapeutics Says Positive Results From A Phase 2a Clinical Trial Of ADX-102 In Patients With Dry Eye Disease
8/8/2017 7:39:17 AM Aldeyra Therapeutics Q2 Net Loss Per Share $0.35 Vs Loss $0.41 Last Year